NeoGenomics Inc. shared a strong financial outlook for 2025 and beyond. The Fort Myers-based cancer testing and research lab ...

NeoGenomics' Chris Smith will retire as CEO and board member, effective April 1, 2025. Tony Zook will assume the role of CEO ...

NeoGenomics said its chief executive, Chris Smith, plans to retire April 1. The Fort Myers, Fla., oncology testing services company on Friday said Tony Zook, an independent board member since 2023, ...

Shares of NeoGenomics, Inc. (NASDAQ: NEO) are, after the company announced that CEO Chris Smith will retire effective April 1 ...

At that time, Tony Zook, an independent board member, will assume the role of CEO. He's been on the board since 2023. Shares fell by more than 17% on the news of a leadership change. To ensure ...

In a report released yesterday, Mark Massaro from BTIG maintained a Buy rating on NeoGenomics (NEO – Research Report), with a price target of ...

Fort Myers-based oncology testing services company Neo Genomics announced Chris Smith will retire as CEO and board member ...

Shares of NeoGenomics tumbled after the oncology testing-services company said its chief executive, Chris Smith, will retire April 1. The stock fell 20%, to $14.91, in afternoon trading Friday. Shares ...

NeoGenomics (NEO) announced that Chris Smith will retire as CEO and board member effective April 1. Tony Zook, an independent board member ...

Tony Zook, an independent board member since 2023, will assume the role of CEO at that time. “Chris has provided exceptional leadership for NeoGenomics, joining the Company at a critical time ...

NeoGenomics has announced a new CEO. The Fort Myers-based cancer testing and research lab, with a national footprint, shared the news Friday, via a press release. Chris Smith, the public company's ...